eGenesis, Inc.

📍 Cambridge, United States🗓 Founded 2015👥 107 employees💰 Last funded Aug 2024
Biotechnology Research🌐 egenesisbio.com
Website LinkedIn
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
5
Total investors
0
Early stage
4
Mid stage
1
Late stage
2015
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
3
Switzerland
1
Germany
1
Investor activity2019–2024 · investors recorded per year
201932020120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in eGenesis, Inc.?
eGenesis, Inc. has 5 investors on record on gritt.io, 4 mid-stage and 1 late-stage investors.
When did eGenesis, Inc. last raise funding?
The most recent investment in eGenesis, Inc. recorded on gritt.io was in August 2024.
When was eGenesis, Inc. founded?
eGenesis, Inc. was founded in 2015.
What industry is eGenesis, Inc. in?
eGenesis, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is eGenesis, Inc. based?
eGenesis, Inc. is headquartered in Cambridge, United States.